Results overview: Found 3 records in 0.03 seconds.
Articles, 3 records found
Articles 3 records found  
12 p, 1.8 MB Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option : a cross-study comparison of the CANDOR and EQUULEUS studies / Leleu, X. (Service d'Hématologie et Thérapie cellulaire. CHU and Inserm) ; Beksac, M. (Department of Hematology. Ankara University) ; Chou, T. (Department of Internal Medicine. Niigata Cancer Center Hospital) ; Dimopoulos, M. (Hematology and Medical Oncology. Department of Clinical Therapeutics. National and Kapodistrian University of Athens School of Medicine) ; Yoon, S.S. (Department of Internal Medicine. Seoul National University) ; Prince, H.M. (Epworth Healthcare and Sir Peter MacCallum Department of Oncology. University of Melbourne) ; Pour, L. (Department of Internal Medicine. Hematology and Oncology. University Hospital Brno) ; Shelekhova, T. (Clinic of Professional Pathology) ; Chari, A. (Tisch Cancer Institute. Icahn School of Medicine at Mount Sinai) ; Khurana, M. (Clinical Development. Oncology. Amgen Inc) ; Zhang, J. (Global Biostatistical Science. Amgen Inc) ; Obreja, M. (Global Biostatistical Science. Amgen Inc) ; Qi, M. (Hematology and Oncology. Janssen Research and Development. LLC) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Siegel, D. (John Theurer Cancer Center. Hackensack University Medical Center) ; Universitat Autònoma de Barcelona
The regimen of carfilzomib, daratumumab, and dexamethasone (KdD) shows activity in patients with relapsed/refractory multiple myeloma. KdD at the twice-weekly 56 mg/m carfilzomib dose (KdD56) was used in the randomized phase 3 CANDOR study (NCT03158688), whereas KdD at the once-weekly 70 mg/m carfilzomib dose (KdD70) was used in the phase 1 b EQUULEUS study (NCT01998971). [...]
2020 - 10.1080/10428194.2020.1832672
Leukemia and Lymphoma, 2020  
8 p, 354.8 KB A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma / Hajek, R. (Faculty of Medicine. University of Ostrava) ; Pour, L. (University Hospital Brno) ; Ozcan, M. (Ankara University School of Medicine) ; Martin Sánchez, J. (Hospital Universitario Virgen del Rocio) ; García Sanz, R. (University Hospital of Salamanca) ; Anagnostopoulos, A. (General Hospital of Thessaloniki "G. Papanikolaou,") ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Cascavilla, N. (IRCCS "Casa Sollievo della Sofferenza" Hospital) ; Terjung, A. (Pharmacyclics Switzerland GmbH. an AbbVie Company) ; Lee, Y. (Pharmacyclics LLC. an AbbVie Company) ; Briso, E.M. (Pharmacyclics Switzerland GmbH. an AbbVie Company) ; Dobkowska, E. (Pharmacyclics Switzerland GmbH. an AbbVie Company) ; Hauns, B. (Pharmacyclics Switzerland GmbH. an AbbVie Company) ; Špička, I. (1st Department of Medicine - Department of Hematology. First Faculty of Medicine. Charles University and General Hospital in Prague) ; Universitat Autònoma de Barcelona
Objective: We evaluated ibrutinib, a once-daily inhibitor of Bruton's tyrosine kinase, combined with bortezomib and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma who had received 1-3 prior therapies. [...]
2020 - 10.1111/ejh.13377
European Journal of Haematology, Vol. 104 Núm. 5 (january 2020) , p. 435-442  
8 p, 788.7 KB A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS) / Hájek, R. (University Hospital Ostrava) ; Masszi, T (St István and St László Hospital of Budapest) ; Petrucci,M.T. (Sapienza Università di Roma) ; Palumbo, A. (Università di Torino) ; Rosiñol, L. (Hospital Clínic de Barcelona) ; Nagler, Arnon. (Chaim Sheba Medical Center (Israel)) ; Yong, K.L. (University College London Cancer Institute) ; Oriol, A. (Institut Germans Trias i Pujol. Institut Català d'Oncologia) ; Minarik, J. (University Hospital Olomouc and Medical Faculty of Palacky) ; Pour, L (University Hospital Ostrava) ; Dimopoulos, M.A. (National and Kapodistrian University of Athens) ; Maisnar, V. (Charles University Teaching Hospital, Hradec Králové) ; Rossi, D. (Amedeo Avogadro University of Eastern Piedmont) ; Kasparu, H. (Hospital Elisabethinen Linz) ; Van Droogenbroeck, J. (AZ Sint-Jan, Brugge, Belgium) ; Yehuda, D.B. (Hadassah Medical Center, Jerusalem, Israel) ; Hardan, I. (Meir Medical Center, Kfar-Saba, Israel) ; Jenner, M. (Southampton General Hospital, Hampshire, UK) ; Calbecka, M. (Nicolaus Copernicus Hospital, Toruń Poland) ; Dávid, M. (University of Pécs, Hungary) ; de la Rubia, J. (Hospital Universitario La Fe, València) ; Drach, J. (Medical University of Vienna) ; Gasztonyi, Z. (Petz Aladár Megyei Oktató Kórház, Vasvári Pál, Hungary) ; Górnik, S. (Zamojski Szpital Niepubliczny, Zamosc, Poland) ; Leleu, X. (Hopital Huriez, CHRU, Lille, France) ; Munder, M. (University Medicine Mainz, Germany) ; Offidani, M (Clinica di Ematologia Azienda Ospedaliero-Universitaria, Ospedali Riuniti di Ancona, Italy) ; Zojer, N. (Center for Oncology, Hematology with Outpatient Department and Palliative Care, Wilhelminenspital, Vienna, Austria) ; Rajangam, K. (Onyx Pharmaceuticals, Inc.) ; Chang, Y.L. (Onyx Pharmaceuticals, Inc.) ; San-Miguel, J.F. (Clínica Universidad de Navarra-CIMA-IDISNA) ; Ludwig, H. (Wilhelminen Cancer Research Institute, Vienna, Austria)
This randomized, phase III, open-label, multicenter study compared carfilzomib monotherapy against low-dose corticosteroids and optional cyclophosphamide in relapsed and refractory multiple myeloma (RRMM). [...]
2017 - 10.1038/leu.2016.176
Leukemia, Vol. 31 (2017) , p. 107-114  

See also: similar author names
1 Pour, L
2 Pour, L.
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.